Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization

J. J. Patten, Patrick T. Keiser, Deisy Morselli-Gysi, Giulia Menichetti, Hiroyuki Mori, Callie J. Donahue, Xiao Gan, Italo do Valle, Kathleen Geoghegan-Barek, Manu Anantpadma, Ruth Mabel Boytz, Jacob L. Berrigan, Sarah H. Stubbs, Tess Ayazika, Colin O'Leary, Sallieu Jalloh, Florence Wagner, Seyoum Ayehunie, Stephen J. Elledge, Deborah AndersonJoseph Loscalzo, Marinka Zitnik, Suryaram Gummuluru, Mark N. Namchuk, Albert László Barabási, Robert A. Davey*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract (may include machine translation)

Pharmacologically active compounds with known biological targets were evaluated for inhibition of SARS-CoV-2 infection in cell and tissue models to help identify potent classes of active small molecules and to better understand host-virus interactions. We evaluated 6,710 clinical and preclinical compounds targeting 2,183 host proteins by immunocytofluorescence-based screening to identify SARS-CoV-2 infection inhibitors. Computationally integrating relationships between small molecule structure, dose-response antiviral activity, host target, and cell interactome produced cellular networks important for infection. This analysis revealed 389 small molecules with micromolar to low nanomolar activities, representing >12 scaffold classes and 813 host targets. Representatives were evaluated for mechanism of action in stable and primary human cell models with SARS-CoV-2 variants and MERS-CoV. One promising candidate, obatoclax, significantly reduced SARS-CoV-2 viral lung load in mice. Ultimately, this work establishes a rigorous approach for future pharmacological and computational identification of host factor dependencies and treatments for viral diseases.

Original languageEnglish
Article number104925
JournaliScience
Volume25
Issue number9
DOIs
StatePublished - 16 Sep 2022

Keywords

  • Bioinformatics
  • Pharmacoinformatics
  • Pharmacology
  • Virology

Fingerprint

Dive into the research topics of 'Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization'. Together they form a unique fingerprint.

Cite this